US4133814A
(en)
|
1975-10-28 |
1979-01-09 |
Eli Lilly And Company |
2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
|
AU509682B2
(en)
|
1975-10-28 |
1980-05-22 |
Eli Lilly And Company |
2-Aroyl-3-Phenylbenzothiophene Derivatives
|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
EP0752421B1
(en)
|
1995-07-07 |
2005-10-12 |
AstraZeneca AB |
Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
|
US6458811B1
(en)
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
AU9399898A
(en)
|
1997-10-03 |
1999-04-27 |
Eli Lilly And Company |
Benzothiophenes
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
US6060488A
(en)
*
|
1998-09-22 |
2000-05-09 |
Eli Lilly And Company |
Benzothiophenes for treating estrogen deficiency
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
US7091240B2
(en)
|
2000-03-10 |
2006-08-15 |
Oxigene, Inc. |
Tubulin binding ligands and corresponding prodrug constructs
|
US6509332B2
(en)
|
2000-07-06 |
2003-01-21 |
Wyeth |
Methods of treating excessive intraocular pressure
|
US20020016318A1
(en)
|
2000-07-06 |
2002-02-07 |
American Home Products Corporation |
Methods of treating breast disorders
|
MXPA02012896A
(es)
|
2000-07-06 |
2003-10-24 |
Wyeth Corp |
Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.
|
CN1452497A
(zh)
|
2000-07-06 |
2003-10-29 |
惠氏公司 |
Ssri和***制剂的联合药物形式
|
WO2002003988A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
WO2002003992A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating prosthesis-related bone degeneration
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
EP1296674A2
(en)
|
2000-07-06 |
2003-04-02 |
Wyeth |
Use of substituted indole compounds for increasing nitric oxide synthase activity
|
CA2415052A1
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Combinations of bisphosphonates, estrogenic agents and optionally estrogens
|
WO2002003989A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
AU2001283139A1
(en)
|
2000-08-11 |
2002-02-25 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
US7371757B2
(en)
|
2003-08-15 |
2008-05-13 |
Astrazeneca Ab |
Fused heterocycles as inhibitors of glutamate racemase(MURI)
|
FR2862646B1
(fr)
|
2003-11-20 |
2006-02-24 |
Merck Sante Sas |
Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
|
WO2006078834A1
(en)
|
2005-01-21 |
2006-07-27 |
Janssen Pharmaceutica N.V. |
Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
AU2007211840B2
(en)
|
2006-02-03 |
2012-03-01 |
Bionomics Limited |
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
|
ES2436028T3
(es)
|
2006-06-23 |
2013-12-26 |
Radius Health, Inc. |
Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
|
EP1947085A1
(en)
|
2007-01-19 |
2008-07-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted indole sulfonamide compounds, their preparation and use as medicaments
|
EP2183237A1
(en)
|
2007-07-25 |
2010-05-12 |
F. Hoffmann-Roche AG |
Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
|
WO2010093578A1
(en)
|
2009-02-10 |
2010-08-19 |
Glaxo Group Limited |
Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
|
WO2010127452A1
(en)
|
2009-05-04 |
2010-11-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ete receptor antagonist compounds
|
CA2800673A1
(en)
|
2010-06-10 |
2011-12-15 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
US9540361B2
(en)
|
2010-12-24 |
2017-01-10 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US9187460B2
(en)
|
2011-12-14 |
2015-11-17 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
MX2014007198A
(es)
|
2011-12-16 |
2014-10-13 |
Olema Pharmaceuticals Inc |
Compuestos novedosos de benzopirano, composiciones y usos de los mismos.
|
BR112014017985A8
(pt)
|
2012-01-31 |
2017-07-11 |
Novartis Ag |
Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
|
US9499538B2
(en)
|
2012-03-20 |
2016-11-22 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
EP2911660B1
(en)
|
2012-10-24 |
2019-12-04 |
The Board of Trustees of the University of Illionis |
Compositions and methods for treating estrogen-related medical disorders
|
EP2912033A4
(en)
|
2012-10-24 |
2016-09-14 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES
|
BR112015018882B1
(pt)
|
2013-02-19 |
2021-09-14 |
Novartis Ag |
Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
|
MX2015011132A
(es)
|
2013-03-14 |
2015-11-30 |
Seragon Pharmaceuticals Inc |
Moduladores policiclicos del receptor de estrogenos y sus usos.
|
PE20160874A1
(es)
|
2013-05-28 |
2016-09-04 |
Astrazeneca Ab |
Compuestos quimicos
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
CA2912853A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulator and uses thereof
|
BR112015030595A2
(pt)
|
2013-06-19 |
2017-07-25 |
Seragon Pharmaceuticals Inc |
moduladores de receptor de estrogênio de azetidina e usos dos mesmos
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2015028409A1
(de)
|
2013-08-27 |
2015-03-05 |
Bayer Pharma Aktiengesellschaft |
6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
MA39741A
(fr)
|
2014-03-13 |
2017-01-18 |
Hoffmann La Roche |
Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
|
CA2941161A1
(en)
|
2014-03-13 |
2015-09-17 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating estrogen receptor mutants
|
SI3122426T1
(sl)
|
2014-03-28 |
2023-04-28 |
Duke University |
Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
|
US9845291B2
(en)
|
2014-12-18 |
2017-12-19 |
Genentech, Inc. |
Estrogen receptor modulators and uses thereof
|
CN112457310A
(zh)
|
2014-12-18 |
2021-03-09 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚***受体调节剂及其用途
|
EP3233818A1
(en)
|
2014-12-18 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
|
JP6768711B2
(ja)
|
2015-05-26 |
2020-10-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
複素環式エストロゲン受容体モジュレーター及びその使用
|
HUE055321T2
(hu)
|
2015-10-01 |
2021-11-29 |
Olema Pharmaceuticals Inc |
Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
|
WO2017056115A1
(en)
|
2015-10-03 |
2017-04-06 |
Sun Pharma Advanced Research Company Limited |
Novel n-aryl containing fused heterocyclic compounds
|
JP2018533561A
(ja)
|
2015-10-07 |
2018-11-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
(e)−3−(4−((e)−2−(2−クロロ−4−フルオロフェニル)−1−(1h−インダゾール−5−イル)ブタ−1−エン−1−イル)フェニル)アクリル酸を調製するためのプロセス
|
DK3368519T3
(da)
|
2015-10-27 |
2022-05-23 |
Sun Pharma Advanced Res Co Ltd |
Hidtil ukendte, heterocykliske antiøstrogener
|
US10118910B2
(en)
|
2015-12-09 |
2018-11-06 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective estrogen receptor downregulators
|
EA034994B1
(ru)
|
2016-02-15 |
2020-04-15 |
Санофи |
6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
|